Baudax Bio, Inc.: 10-Q filed 2019-11-14
What Baudax Bio, Inc. reported in its quarterly report filed 2019-11-14 (fiscal Q3 2019): 27 published measures, 69 facts as tagged in accession 0001564590-19-043554.
This filing
- Form
- 10-Q (quarterly report)
- Filed
- 2019-11-14
- Fiscal period
- fiscal Q3 2019
- Accession
- 0001564590-19-043554 on SEC EDGAR
Values are as tagged in this filing. A later filing can restate them; each measure links to its history page, which shows the latest-filed value per period. All Baudax Bio, Inc. filings.
Reported measures
Total assets
Resources recognized on the balance sheet. Book assets are not the market value of the business.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2019-09-30 | 35,985,000 | USD | |
| At 2018-12-31 | 35,023,000 | USD |
Total liabilities
Recognized obligations at the reporting date. The definition and scope differ from interest-bearing debt.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2019-09-30 | 71,408,000 | USD | |
| At 2018-12-31 | 103,370,000 | USD |
Net income or loss
Reported profit or loss for the period. Check the filing for attribution, exceptional items and discontinued operations before comparing companies.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2019-07-01 to 2019-09-30 | -10,315,000 | USD | 92 |
| 2019-01-01 to 2019-09-30 | -25,232,000 | USD | 273 |
| 2019-04-01 to 2019-06-30 | -10,582,000 | USD | 91 |
| 2019-01-01 to 2019-03-31 | -4,335,000 | USD | 90 |
| 2018-07-01 to 2018-09-30 | -19,092,000 | USD | 92 |
| 2018-01-01 to 2018-09-30 | -56,986,000 | USD | 273 |
| 2018-04-01 to 2018-06-30 | -20,437,000 | USD | 91 |
| 2018-01-01 to 2018-03-31 | -17,457,000 | USD | 90 |
Operating cash flow
Cash generated or used by operating activities. Working-capital timing can make this differ substantially from reported income.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2019-01-01 to 2019-09-30 | -42,104,000 | USD | 273 |
| 2018-01-01 to 2018-09-30 | -46,848,000 | USD | 273 |
Capital expenditure payments
Cash payments to acquire property, plant and equipment. This taxonomy concept does not capture every form of investment or acquisition.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2019-01-01 to 2019-09-30 | 1,633,000 | USD | 273 |
| 2018-01-01 to 2018-09-30 | 2,118,000 | USD | 273 |
Financing cash flow
Net cash from financing activities, including borrowing, repayments and transactions with owners. A positive amount does not establish operating profitability.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2019-01-01 to 2019-09-30 | 43,902,000 | USD | 273 |
| 2018-01-01 to 2018-09-30 | 49,048,000 | USD | 273 |
Investing cash flow
Net cash from investing activities, including asset purchases, disposals and investment transactions. This differs from capital expenditure payments alone.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2019-01-01 to 2019-09-30 | -1,798,000 | USD | 273 |
| 2018-01-01 to 2018-09-30 | -2,200,000 | USD | 273 |
Net property, plant and equipment
Carrying amount of property, plant and equipment after accumulated depreciation, depletion and amortization. It is not replacement cost or market value.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2019-09-30 | 4,968,000 | USD | |
| At 2018-12-31 | 3,982,000 | USD |
Share-based compensation expense
Reported noncash expense for share-based payment arrangements. Noncash treatment does not mean the awards have no economic cost to shareholders.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2019-01-01 to 2019-09-30 | 4,254,000 | USD | 273 |
| 2018-01-01 to 2018-09-30 | 3,370,000 | USD | 273 |
Operating income or loss
Operating revenue less operating expenses for the reporting period. It excludes items outside the reported operating result and is not free cash flow.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2019-07-01 to 2019-09-30 | -10,278,000 | USD | 92 |
| 2019-01-01 to 2019-09-30 | -25,146,000 | USD | 273 |
| 2018-07-01 to 2018-09-30 | -19,060,000 | USD | 92 |
| 2018-01-01 to 2018-09-30 | -56,864,000 | USD | 273 |
Current assets
Assets classified as current under the normal operating cycle or one-year boundary. Not all current assets can be converted immediately into cash.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2019-09-30 | 1,658,000 | USD | |
| At 2018-12-31 | 2,514,000 | USD |
Current liabilities
Obligations classified as current under the operating-cycle or one-year boundary. The balance includes more than short-term borrowing.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2019-09-30 | 5,217,000 | USD | |
| At 2018-12-31 | 22,780,000 | USD |
Current accounts payable
Current amounts owed to suppliers for goods and services received. This is one component of current liabilities, not all accrued obligations.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2019-09-30 | 361,000 | USD | |
| At 2018-12-31 | 2,653,000 | USD |
Goodwill carrying amount
Recognized goodwill remaining after accumulated impairment. It arises from business combinations and does not measure the current value of the company’s brand.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2019-09-30 | 2,127,000 | USD | |
| At 2018-12-31 | 2,127,000 | USD |
Operating expenses
Recurring operating costs under this accounting concept, generally excluding production costs included in cost of sales. Check filing presentation before combining expense subtotals.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2019-07-01 to 2019-09-30 | 10,278,000 | USD | 92 |
| 2019-01-01 to 2019-09-30 | 25,146,000 | USD | 273 |
| 2018-07-01 to 2018-09-30 | 19,060,000 | USD | 92 |
| 2018-01-01 to 2018-09-30 | 56,864,000 | USD | 273 |
Research and development expense
Research and development costs recognized as expense. Capitalization policies and acquired projects can make this differ from total cash invested in development.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2019-07-01 to 2019-09-30 | 1,845,000 | USD | 92 |
| 2019-01-01 to 2019-09-30 | 18,578,000 | USD | 273 |
| 2018-07-01 to 2018-09-30 | 9,838,000 | USD | 92 |
| 2018-01-01 to 2018-09-30 | 25,664,000 | USD | 273 |
Operating lease right-of-use asset
Carrying amount of the right to use leased assets under operating leases. It reflects discounted remaining payments, not the value of the underlying property.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2019-09-30 | 832,000 | USD |
Operating lease liability
Present value of remaining operating lease payments. Discount-rate choices and lease terms affect the amount; it is not the sum of undiscounted future rent.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2019-09-30 | 876,000 | USD |
Gross property, plant and equipment
Cost of property, plant and equipment before accumulated depreciation. Historical cost does not indicate current value or replacement cost.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2019-09-30 | 5,776,000 | USD | |
| At 2018-12-31 | 4,454,000 | USD |
Accumulated depreciation on property, plant and equipment
Cumulative depreciation, depletion and amortization recorded against property, plant and equipment. It measures cost allocation to date, not physical wear or market value.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2019-09-30 | 808,000 | USD | |
| At 2018-12-31 | 472,000 | USD |
Other noncurrent liabilities
Noncurrent liabilities the filer does not present separately. The composition differs by filer and is described only in the filing.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2018-12-31 | 32,000 | USD |
Prepaid expenses and other current assets
Prepayments and other current assets grouped under this concept. The balance is not cash and its composition differs by filer.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2019-09-30 | 1,658,000 | USD | |
| At 2018-12-31 | 2,514,000 | USD |
Profit or loss including noncontrolling interests
Net income or loss including the portion attributable to noncontrolling interests. It can differ from the net income attributable to the parent that per-share figures use.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2019-01-01 to 2019-09-30 | -25,232,000 | USD | 273 |
| 2018-01-01 to 2018-09-30 | -56,986,000 | USD | 273 |
General and administrative expense
General and administrative costs reported under this concept, separate from selling expense. Filers group overhead differently, so compare presentation before comparing companies.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2019-07-01 to 2019-09-30 | 4,524,000 | USD | 92 |
| 2019-01-01 to 2019-09-30 | 21,809,000 | USD | 273 |
| 2018-07-01 to 2018-09-30 | 5,107,000 | USD | 92 |
| 2018-01-01 to 2018-09-30 | 24,170,000 | USD | 273 |
Depreciation expense
Depreciation recognized for the period under this concept. It is a noncash allocation of asset cost and may exclude amortization and depletion reported elsewhere.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2019-07-01 to 2019-09-30 | 123,000 | USD | 92 |
| 2019-01-01 to 2019-09-30 | 369,000 | USD | 273 |
| 2018-07-01 to 2018-09-30 | 161,000 | USD | 92 |
| 2018-01-01 to 2018-09-30 | 273,000 | USD | 273 |
Amortization of intangible assets
Amortization recognized on finite-lived intangible assets. It follows acquisition accounting and does not indicate the intangibles are losing usefulness at that rate.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2019-01-01 to 2019-09-30 | 0 | USD | 273 |
| 2018-01-01 to 2018-09-30 | 0 | USD | 273 |
Nonoperating income or expense
Total nonoperating income or expense, which can include interest, investment results and other items. A positive value is not operating profit.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2019-07-01 to 2019-09-30 | -37,000 | USD | 92 |
| 2019-01-01 to 2019-09-30 | -86,000 | USD | 273 |
| 2018-07-01 to 2018-09-30 | -32,000 | USD | 92 |
| 2018-01-01 to 2018-09-30 | -122,000 | USD | 273 |
Inspect the source
- Entity
- Baudax Bio, Inc. / CIK 0001780097
- Captured
- SEC response SHA-256
30dcf52bf938a3b74d7262773a79200067d86adf90995625ac565a1cb0243add
Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON
Every published concept a filing tagged, with the periods it covered, as reported in that filing at capture time. Forms 10-K, 10-K/A, 10-Q, 10-Q/A, 20-F, 20-F/A, 40-F, 40-F/A. A filing page needs at least 8 published concepts. Later filings can restate these values; the company history pages show the latest-filed value per period.
Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.
Use this in research
A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.
These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.
Research methodology · Execution and cost assumptions · Check backtest overfitting
Build with the open-source tools
Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.
- Get an API key and run your first validation
- Connect the MCP server to your coding assistant
- Inspect the ALPHAC engine on GitHub
- Read the MCP server source and integration examples
Read the published dataset with Python
import json
from urllib.request import urlopen
with urlopen("https://canlicapital.com/company-data/0001780097.json") as response:
record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
print(concept["tag"], next(iter(concept["observations"])))